Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.
The FDA has approved quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.
Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.
Treatment with the CD3 x CD123 bispecific antibody APVO436 plus venetoclax and azacitidine led to durable remissions in patients with relapsed/refractory acute myeloid leukemia who had not received prior venetoclax.
Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.
Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.
The US Oncology Network announced that the Cancer Center of Kansas has joined The Network by entering into a new managed services partnership.
China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.
The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
Bexmarilimab in combination with standard-of-care azacitidine or azacitidine plus venetoclax demonstrated early signs of efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.
Ahmed Elkhanany, MD discusses unmet needs in patients with estrogen receptor–positive breast cancer who progress on frontline therapy, treatment considerations for these patients, and how FES PET imaging may benefit this population.
Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.
Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.
Finding a comprehensive cancer care provider that is able to provide patients with swift and easy access to the highest-quality diagnosis and treatment planning is essential to reducing stress and ensuring patients achieve the best possible outcomes.
The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, improved progression-free survival vs concurrent chemoradiotherapy alone in newly diagnosed patients with high-risk locally advanced cervical cancer.
The FDA has granted a fast track designation to selinexor for use in the treatment of patients with myelofibrosis, including primary myelofibrosis, post–essential thrombocytopenia myelofibrosis, and post–polycythemia vera myelofibrosis.
Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with metastatic colorectal cancer.
The third-generation EGFR TKI lazertinib displayed a significant efficacy improvement compared with gefitinib in patients with EGFR-mutated advanced non–small cell lung cancer when given in the first-line.
Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management.
Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.
Shannon Westin, MD, MPH, FACOG, expands on key clinical trial updates in gynecologic oncology shared at the 2023 ASCO Annual Meeting and highlights what she is looking forward to seeing in the future of care for patients with gynecologic malignancies.
The novel bifunctional fusion protein SHR-1701 combined with standard first-line treatment with the bevacizumab biosimilar BP102 and platinum-doublet chemotherapy produced high, durable responses and was deemed tolerable in patients with cervical cancer.
The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
The allogeneic CAR T-cell therapy CB-010 demonstrated early signs of durable antitumor activity and favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Press Release
Cedars-Sinai Cancer investigators elucidate how this process allows bladder tumors to evade the immune system but also makes them vulnerable to a common treatment.
The FDA has granted an orphan drug designation to gallium maltolate for use as a potential therapeutic option in pediatric patients with glioblastoma multiforme.
Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.
Patients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic renal cell carcinoma.
